spacer
home > epc > spring 2009 > beyond technology
PUBLICATIONS
European Pharmaceutical Contractor

Beyond Technology

As electronic data capture (EDC) is becoming the standard for clinical trials, CROs are under pressure to offer this system and carry out projects that competitively meet time, cost and quality demands. Decisions about the choice of EDC partner must take the sponsorís interests into account in order to establish an efficient collaboration. EDC vendors are advised to offer special programmes for this purpose.

STRATEGIC EDC PARTNERSHIPS

According to Thomson CenterWatch, the proportion of EDC studies in 2007 exceeded the 40 per cent mark for the first time, with respect to all clinical studies commissioned worldwide (1). Furthermore, it is predicted that this technology will become the standard by 2010. Since further prognoses indicate that the market tends towards standardisation of EDC systems, many CROs choose not to develop their own system and instead work together with specialised EDC vendors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Claudia Horneck is the Director PR/Promotion of clinIT AG, but also works as a selfemployed Consultant working closely with pharmaceutical contract research organisations. She received her Masters in German Literature, Linguistics and Philosophy from the Albert-Ludwigs University, Freiburg, Germany. Prior to her position at clinIT AG, Claudia held the positions of Head of Sales Administration and Customer Relations Manager at Thomae & Partner AG, Freiburg.

spacer
Claudia Horneck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: itís where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on todayís hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement